Phase I dose-escalation trial investigating the safety and tolerability of EP0906 plus estramustine in patients with advanced cancer.

被引：0
|
作者：
Wojtowicz, M
Rothermel, JD
Anderson, J
Todd, M
Rubin, EH
Dipaola, RS
机构：
[1] Canc Inst New Jersey, New Brunswick, NJ USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4623
引用
收藏
页码：412S / 412S
页数：1
相关论文
共 50 条
  • [11] Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer
    Hochster, Howard
    Kettner, Erika
    Kroening, Hendrik
    Becker, Klaus
    Lordick, Florian
    Ramanathan, Ramesh K.
    Macdonald, John
    Hong, Shengyan
    John, William
    Schmoll, Hans-Joachim
    CLINICAL COLORECTAL CANCER, 2005, 5 (04) : 257 - 262
  • [12] Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Bleickardt, E
    Argiris, A
    Rich, R
    Blum, K
    McKeon, A
    Tara, H
    Zelterman, D
    Burtness, B
    Davies, MJ
    Murren, JR
    CANCER BIOLOGY & THERAPY, 2002, 1 (06) : 646 - 651
  • [13] Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
    Marshall, John
    Shapiro, Geoffrey I.
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Stopfer, Peter
    Gordon, Michael S.
    FUTURE ONCOLOGY, 2013, 9 (02) : 271 - 281
  • [14] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    R D Kim
    S R Alberts
    C Peña
    I Genvresse
    A Ajavon-Hartmann
    C Xia
    A Kelly
    J E Grilley-Olson
    British Journal of Cancer, 2018, 118 : 462 - 470
  • [15] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470
  • [16] A phase I dose-escalation study to evaluate pharmacokinetics, safety and tolerability of ACT001 in patients with advanced glioma.
    Shi, Yehui
    Bai, Guiying
    Wang, Peng
    Cai, Dongpo
    Chen, Yue
    Wang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [17] A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
    Hegde, Aparna
    Jayaprakash, Priyamvada
    Couillault, Coline A.
    Piha-Paul, Sarina
    Karp, Daniel
    Rodon, Jordi
    Pant, Shubham
    Fu, Siqing
    Dumbrava, Ecaterina E.
    Yap, Timothy A.
    Subbiah, Vivek
    Bhosale, Priya
    Coarfa, Cristian
    Higgins, Jack P.
    Williams, Eric T.
    Wilson, Thomas F.
    Lim, JoAnn
    Meric-Bernstam, Funda
    Sumner, Elizabeth
    Zain, Hira
    Di Nguyen
    Nguyen, Ly M.
    Rajapakshe, Kimal
    Curran, Michael A.
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3050 - 3060
  • [18] A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
    Greil, Richard
    Greil-Ressler, Sigrun
    Weiss, Lukas
    Schoenlieb, Charlotte
    Magnes, Teresa
    Radl, Bianca
    Bolger, Gordon T.
    Vcelar, Brigitta
    Sordillo, Peter P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 695 - 706
  • [19] A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
    Richard Greil
    Sigrun Greil-Ressler
    Lukas Weiss
    Charlotte Schönlieb
    Teresa Magnes
    Bianca Radl
    Gordon T. Bolger
    Brigitta Vcelar
    Peter P. Sordillo
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 695 - 706
  • [20] Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
    Bayet-Robert, Mathilde
    Kwiatkowski, Fabrice
    Leheurteur, Marianne
    Gachon, Francoise
    Planchat, Eloise
    Abrial, Catherine
    Mouret-Reynier, Marie-Ange
    Durando, Xavier
    Barthomeuf, Chantal
    Chollet, Philippe
    CANCER BIOLOGY & THERAPY, 2010, 9 (01) : 8 - 14
12345